Can We Delay Alzheimer's Symptoms Before They Begin? Inside the PrevenTRON Trial
Episode description: Dr. Geoff Kerchner, Vice President and Global Head of Neurodegeneration at Roche, Basel, Switzerland, discusses the science behind PrevenTRON, a prevention study evaluating trontinemab in individuals with preclinical Alzheimer disease. Keywords: trontinemab, Alzheimer's, Alzheimer disease, dementia, mild cognitive impairment, MCI, amyloid-targeting therapies, Roche, PrevenTRON, TRONTIER, brain health, cognitive health
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from NeuroFrontiers
Subcutaneous Lecanemab for Early Alzheimer Disease: Evidence, Safety, and Patient Selection
Next-Generation CNS Drug Delivery: Brainshuttle Technology and Clinical Implications in Alzheimer Disease
Advancing MOGAD Care
Generalized Myasthenia Gravis: Inside the MINT Trial and CD19 B-Cell Therapy Advances
Get summaries like this every morning.
Free AI-powered recaps of NeuroFrontiers and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.